secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-204006
Event type: other
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share
--------------------------------------------------------------------------

- Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
- Underwriter granted 45-day option for up to 7.5M additional shares; warrants for 3% of sold shares at $1.50.
- Bios entities defer conversion of 12,232 Series X preferred shares and lock-up through April 2029; receive 3M warrants at $1.00.
- Proceeds to fully fund Phase 2 trial of LTI-03 in IPF; cash runway extended into 2028.
- Konik Capital Partners (T.R. Winston) acts as sole book-running manager.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/0001193125-26-204006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312526204006/d168655d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-204006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer